Meropenem use and colonization by antibiotic-resistant Gram-negative bacilli in a pediatric intensive care unit

Pediatric Critical Care Medicine

Volumn 10, Issue 1, 2009, Pages 49-54

  Toltzis, Philip ^a   Dul, Michael ^b   O'Riordan, Mary Ann ^a   Melnick, David ^c   Lo, Mathew ^c   Blumer, Jeffrey ^d  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c ASTRAZENECA   (United Kingdom)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Antibiotic resistance; Antibiotic utilization; Bacterial colonization; Carbapenem; Gram negative bacilli; Nosocomial infections

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM; BETA LACTAMASE INHIBITOR; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; MACROLIDE; MEROPENEM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL INFECTION; CHILD; COMPARATIVE STUDY; CRITICALLY ILL PATIENT; DRUG PREFERENCE; DRUG USE; GRAM NEGATIVE BACTERIUM; HOSPITAL ADMISSION; HOSPITAL INFECTION; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ANTIBIOTIC PROPHYLAXIS; CHILD; CHILD, PRESCHOOL; COLONY COUNT, MICROBIAL; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; FEMALE; FOLLOW-UP STUDIES; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INCIDENCE; INFANT; INTENSIVE CARE UNITS, PEDIATRIC; MALE; MICROBIAL SENSITIVITY TESTS; PROBABILITY; PROSPECTIVE STUDIES; RISK ASSESSMENT; THIENAMYCINS; TREATMENT OUTCOME;

EID: 70349200960     PISSN: 15297535     EISSN: None     Source Type: Journal    
DOI: 10.1097/PCC.0b013e318193691a     Document Type: Article

References (32)

1. Toltzis P, Yamashita T, Vilt L, et al: Colonization with antibiotic-resistant gram-negative organisms in a pediatric intensive care unit. Crit Care Med 1997; 25:538-544
2. Cosgrove SE: The relationship between antimicrobial resistance and patient outcomes: Mortality, length of hospital stay, and health care costs. Clin Infect Dis 2006; 42(Suppl 2):S82-S89
3. Ibrahim EH, Sherman G, Ward S, et al: The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118:146-155
4. Kang CI, Kim SH, Park WB, et al: Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: Risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Anti-microb Agents Chemother 2005; 49:760-766
5. Kollef MH, Sherman G, Ward S, et al: Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 462-474
6. Micek ST, Lloyd AE, Ritchie DJ, et al: Pseudomonas aeruginosa bloodstream infection: Importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005; 49:1306-1311
7. Zhanel GG, Wiebe R, Dilay L, et al: Comparative review of the carbapenems. Drugs 2007; 67:1027-1052
8. Jacoby GA, Munoz-Price LS: The new beta-lactamases. N Engl J Med 2005; 352:380-391
9. Paterson DL, Bonomo RA: Extended-spectrum beta-lactamases: A clinical update. Clin Microbiol Rev 2005; 18:657-686
10. Pollack MM, Ruttimann UE, Getson PR: Pediatric risk of mortality (PRISM) score. Crit Care Med 1988; 16:1110-1116
11. Ortiz-Ruiz G, Vetter N, Isaacs R, Carides A, et al: Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: Combined analysis of two mul-ticentre randomized, double-blind studies. J Antimicrob Chemother 2004; 53(Suppl 2): ii59-ii66
12. Zanetti G, Bally F, Greub G, et al: Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: A multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 2003; 47:3442-3447
13. Mehtar S, Dewar EP, Leaper DJ, et al: A multi-centre study to compare meropenem and cefotaxime and metronidazole in the treatment of hospitalized patients with serious infections. J Antimicrob Chemother 1997; 39:631-638
14. Wilson SE: Results of a randomized, multicenter trial of meropenem versus clindamycin/tobramycin for the treatment of intra-abdominal infections. Clin Infect Dis 1997; 24(Suppl 2):S197-S206
15. Tomera KM, Burdmann EA, Reyna OG, et al: Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: Results of a prospective, randomized, double-blind multicenter study. Antimicrob Agents Chemother 2002; 46:2895-2900
16. Feld R, DePauw B, Berman S, et al: Mero-penem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: A randomized, double-blind trial. J Clin Oncol 2000; 18:3690-3698
17. Fleischhack G, Hartmann C, Simon A, et al: Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer. J Antimicrob Chemother 2001; 47:841-853
18. Norrby SR, Gildon KM: Safety profile of meropenem: A review of nearly 5,000 patients treated with meropenem. Scand J Infect Dis 1999; 31:3-10
19. Odio CM, Puig JR, Feris JM, et al: Prospective, randomized, investigator-blinded study of the efficacy and safety of meropenem vs. cefotaxime therapy in bacterial meningitis in children. Meropenem Meningitis Study Group. Pediatr Infect Dis J 1999; 18:581-590
20. Georges B, Conil JM, Dubouix A, et al: Risk of emergence of Pseudomonas aeruginosa resistance to beta-lactam antibiotics in intensive care units. Crit Care Med 2006; 34: 1636-1641
21. Harris A, Torres-Viera C, Venkataraman L, et al: Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa. Clin Infect Dis 1999; 28: 1128-1133
22. Paramythiotou E, Lucet JC, Timsit JF, et al: Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: Role of antibiotics with antipseudomonal activity. Clin Infect Dis 2004; 38: 670-677
23. Carmeli Y, Troillet N, Eliopoulos GM, et al: Emergence of antibiotic-resistant Pseudomonas aeruginosa: Comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999; 43:1379-1382
24. Quale J, Bratu S, Gupta J, et al: Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2006; 50:1633-1641
25. Richards MJ, Edwards JR, Culver DH, et al: Nosocomial infections in pediatric intensive care units in the United States. National Nos-ocomial Infections Surveillance System. Pediatrics 1999; 103:e39
26. Livermore DM, Sefton AM, Scott GM: Properties and potential of ertapenem. J Antimi-crob Chemother 2003; 52:331-344
27. Ghanem G, Hachem R, Jiang Y, et al: Outcomes for and risk factors associated with vancomycin-resistant Enterococcus faecalis and vancomycin-resistant Enterococcus faecium bacteremia in cancer patients. Infect Control Hosp Epidemiol 2007; 28: 1054-1059
28. Poirel L, Nordmann P: Carbapenem resistance in Acinetobacter baumannii: Mechanisms and epidemiology. Clin Microbiol Infect 2006; 12:826-836
29. Koprnova J, Svetlansky I, Bilikova E, et al: Acinetobacter baumanii bacteremia in children. Pediatr Infect Dis J 2001; 20:1183
30. Katragkou A, Kotsiou M, Antachopoulos C, et al: Acquisition of imipenem-resistant Acin-etobacter baumannii in a pediatric intensive care unit: A case-control study. Intensive Care Med 2006; 32:1384-1391
31. Dellit TH, Owens RC, McGowan JE Jr, et al: Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44:159-177
32. Zaoutis TE, Goyal M, Chu JH, et al: Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children. Pediatrics 2005; 115:942-949